Exclusive: Sanofi, Astellas venture arms add cash to Avilar's 'ATAC' mission
The venture arms of Sanofi and Astellas have grown their investment in Avilar Therapeutics to help steer the biotech through a niche of the growing protein degradation field.
Medical Excellence Capital also joined the Big Pharma’s investment teams, along with original investor RA Capital. The company originally announced a $60 million commitment from RA Capital in 2021, with the round now at $75 million, CEO Daniel Grau told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.